Switch theme
Sign up to access all valuation multiples
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy.
1998
7
LTM Revenue n/a
LTM EBITDA -$3.3M
$32.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Active Biotech has a last 12-month revenue of n/a and a last 12-month EBITDA of -$3.3M.
In the most recent fiscal year, Active Biotech achieved revenue of n/a and an EBITDA of -$4.0M.
Active Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Active Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$4.6M | -$4.0M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$6.1M | -$4.8M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 28, 2025, Active Biotech's stock price is SEK 0 (or $0).
Active Biotech has current market cap of SEK 330M (or $34.7M), and EV of SEK 305M (or $32.1M).
See Active Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32.1M | $34.7M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 28, 2025, Active Biotech has market cap of $34.7M and EV of $32.1M.
Active Biotech's trades at n/a LTM EV/Revenue multiple, and -9.7x LTM EBITDA.
Analysts estimate Active Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Active Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $32.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -8.1x | XXX | XXX | XXX |
| P/E | -8.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialActive Biotech's NTM/LTM revenue growth is Infinity%
Active Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Active Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Active Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Active Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | N/A | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | -14% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Active Biotech acquired XXX companies to date.
Last acquisition by Active Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Active Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Active Biotech founded? | Active Biotech was founded in 1998. |
| Where is Active Biotech headquartered? | Active Biotech is headquartered in Sweden. |
| How many employees does Active Biotech have? | As of today, Active Biotech has 7 employees. |
| Who is the CEO of Active Biotech? | Active Biotech's CEO is Ms. Helen Tuvesson. |
| Is Active Biotech publicy listed? | Yes, Active Biotech is a public company listed on STO. |
| What is the stock symbol of Active Biotech? | Active Biotech trades under ACTI ticker. |
| When did Active Biotech go public? | Active Biotech went public in 2000. |
| Who are competitors of Active Biotech? | Similar companies to Active Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Active Biotech? | Active Biotech's current market cap is $34.7M |
| What is the current EBITDA of Active Biotech? | Active Biotech's last 12-month EBITDA is -$3.3M. |
| What is the current EV/EBITDA multiple of Active Biotech? | Current EBITDA multiple of Active Biotech is -9.7x. |
| Is Active Biotech profitable? | Yes, Active Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
